Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice
© 2019 American Cancer Society..
BACKGROUND: Patient-derived xenograft (PDX) models increasingly are used in translational research. However, the engraftment rates of patient tumor samples in immunodeficient mice to PDX models vary greatly.
METHODS: Tumor tissue samples from 308 patients with non-small cell lung cancer were implanted in immunodeficient mice. The patients were followed for 1.5 to approximately 6 years. The authors performed histological analysis of PDXs and some residual tumor tissues in mice with failed PDX growth at 1 year after implantation. Quantitative polymerase chain reaction and enzyme-linked immunoadsorbent assay were performed to measure the levels of Epstein-Barr virus genes and human immunoglobulin G in PDX samples. Patient characteristics were compared for PDX growth and overall survival as outcomes using Cox regression analyses. Disease staging was based on the 7th TNM staging system.
RESULTS: The overall engraftment rate for PDXs from patients with non-small cell lung cancer was 34%. Squamous cell carcinomas had a higher engraftment rate (53%) compared with adenocarcinomas. Tumor samples from patients with stage II and stage III disease and from larger tumors were found to have relatively high engraftment rates. Patients whose tumors successfully engrafted had worse overall survival, particularly those individuals with adenocarcinoma, stage III or stage IV disease, and moderately differentiated tumors. Lymphoma formation was one of the factors associated with engraftment failure. Human CD8-positive and CD20-positive cells were detected in residual samples of tumor tissue that failed to generate a PDX at 1 year after implantation. Human immunoglobulin G was detected in the plasma of mice that did not have PDX growth at 14 months after implantation.
CONCLUSIONS: The results of the current study indicate that the characteristics of cancer cells and the tumor immune microenvironment in primary tumors both can affect engraftment of a primary tumor sample.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:125 |
|---|---|
| Enthalten in: |
Cancer - 125(2019), 21 vom: 01. Nov., Seite 3738-3748 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Yungchang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigens, CD20 |
|---|
| Anmerkungen: |
Date Completed 26.05.2020 Date Revised 26.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cncr.32366 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299008452 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299008452 | ||
| 003 | DE-627 | ||
| 005 | 20231225095413.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cncr.32366 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0996.xml |
| 035 | |a (DE-627)NLM299008452 | ||
| 035 | |a (NLM)31287557 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Yungchang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.05.2020 | ||
| 500 | |a Date Revised 26.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 American Cancer Society. | ||
| 520 | |a BACKGROUND: Patient-derived xenograft (PDX) models increasingly are used in translational research. However, the engraftment rates of patient tumor samples in immunodeficient mice to PDX models vary greatly | ||
| 520 | |a METHODS: Tumor tissue samples from 308 patients with non-small cell lung cancer were implanted in immunodeficient mice. The patients were followed for 1.5 to approximately 6 years. The authors performed histological analysis of PDXs and some residual tumor tissues in mice with failed PDX growth at 1 year after implantation. Quantitative polymerase chain reaction and enzyme-linked immunoadsorbent assay were performed to measure the levels of Epstein-Barr virus genes and human immunoglobulin G in PDX samples. Patient characteristics were compared for PDX growth and overall survival as outcomes using Cox regression analyses. Disease staging was based on the 7th TNM staging system | ||
| 520 | |a RESULTS: The overall engraftment rate for PDXs from patients with non-small cell lung cancer was 34%. Squamous cell carcinomas had a higher engraftment rate (53%) compared with adenocarcinomas. Tumor samples from patients with stage II and stage III disease and from larger tumors were found to have relatively high engraftment rates. Patients whose tumors successfully engrafted had worse overall survival, particularly those individuals with adenocarcinoma, stage III or stage IV disease, and moderately differentiated tumors. Lymphoma formation was one of the factors associated with engraftment failure. Human CD8-positive and CD20-positive cells were detected in residual samples of tumor tissue that failed to generate a PDX at 1 year after implantation. Human immunoglobulin G was detected in the plasma of mice that did not have PDX growth at 14 months after implantation | ||
| 520 | |a CONCLUSIONS: The results of the current study indicate that the characteristics of cancer cells and the tumor immune microenvironment in primary tumors both can affect engraftment of a primary tumor sample | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a neoplasia | |
| 650 | 4 | |a non-small cell lung cancer (NSCLC) | |
| 650 | 4 | |a tumor microenvironment tumor models | |
| 650 | 4 | |a xenografts | |
| 650 | 7 | |a Antigens, CD20 |2 NLM | |
| 700 | 1 | |a Zhang, Ran |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Correa, Arlene M |e verfasserin |4 aut | |
| 700 | 1 | |a Pataer, Apar |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiaoshan |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Chenghui |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Shuhong |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Qing H |e verfasserin |4 aut | |
| 700 | 1 | |a Fujimoto, Junya |e verfasserin |4 aut | |
| 700 | 1 | |a Jensen, Vanessa B |e verfasserin |4 aut | |
| 700 | 1 | |a Antonoff, Mara B |e verfasserin |4 aut | |
| 700 | 1 | |a Hofstetter, Wayne L |e verfasserin |4 aut | |
| 700 | 1 | |a Mehran, Reza J |e verfasserin |4 aut | |
| 700 | 1 | |a Pisimisis, George |e verfasserin |4 aut | |
| 700 | 1 | |a Rice, David C |e verfasserin |4 aut | |
| 700 | 1 | |a Sepesi, Boris |e verfasserin |4 aut | |
| 700 | 1 | |a Vaporciyan, Ara A |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, Garrett L |e verfasserin |4 aut | |
| 700 | 1 | |a Swisher, Stephen G |e verfasserin |4 aut | |
| 700 | 1 | |a Roth, Jack A |e verfasserin |4 aut | |
| 700 | 1 | |a Heymach, John V |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Bingliang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer |d 1948 |g 125(2019), 21 vom: 01. Nov., Seite 3738-3748 |w (DE-627)NLM000028649 |x 1097-0142 |7 nnns |
| 773 | 1 | 8 | |g volume:125 |g year:2019 |g number:21 |g day:01 |g month:11 |g pages:3738-3748 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cncr.32366 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 125 |j 2019 |e 21 |b 01 |c 11 |h 3738-3748 | ||